Mississauga, ON -- (SBWIRE) -- 11/01/2013 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Transgenomic Signs Collaboration Agreement with PerkinElmer for Worldwide Rights to Cancer Detection Tools.”
Companies mentioned in this article include Trovagene, Inc. (Nasdaq:TROV), Aethlon Medical Inc. (OTCQB:AEMD), Transgenomic, Inc. (OTCBB:TBIO), PerkinElmer, Inc. (NYSE:PKI) and PDI, Inc. (Nasdaq:PDII).
Article Excerpt:
There’s a lot of buzz in the biotechnology arena lately surrounding colon cancer, especially related to the Kirsten rat sarcoma viral oncogene homolog, better known as the KRAS gene. The gene is important as it is integral in making the K-Ras protein that is involved in regulating cell division. Cancer, in its simplest sense, is cell division gone wild, so that explains why genes involved in the cell division process are critical in controlling cancer. In many cancers, regardless of origin, genes are mutated in some fashion, prohibiting them from accurately performing vital functions. It’s notable that it’s not true in every case, as exemplified recently by Merck KGaA to narrow the indication for its advanced colon cancer drug Erbitux for the treatment of epidermal growth factor receptor (EGFR)-expressing tumors without a mutation in the KRAS gene.
Several companies are making big strides in molecular diagnostics, an industry that has grown about 70 percent to $6.2 billion in the past six years. Trovagene, Inc. (Nasdaq:TROV) is making headlines with its urine analysis technologies and upstart Aethlon Medical Inc. (OTCQB:AEMD) has popped on the scene with tools to detect and quantify exosomes in biological fluid to identify a range of diseases.
Transgenomic, Inc. (OTCBB:TBIO), an international biotech with its headquarters in Omaha, Nebraska, is another junior making waves with its advancements in personalized medicine in the fields of oncology, cardiology and inherited diseases. The company operates through three divisions, including a business focused on diagnostic testing.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/403/transgenomic-signs-collaboration-agreement-with-perkinelmer-for-worldwide-rights-to-cancer-detection-tools.htm
About AllPennyStocks.com:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.